Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We are lingering at a half a penny!! geeeez
well, that isnt too in depth, but, that would be great to see more expansion and growth
yo Billy!! work your magic!
the break is coming, ninja boy!!
GETA starting up a run???
great time to jump on with some cheapies
Things moving well here thru the morning session, more to come this afternoon
oh sorry ... I was on something else there ... sorry
thats what I'm here for ... positivity without even saying a word
whats up man??? what you saying???
things are moving slowly but surely
you just can never tell what starts a run or what starts a downfall
interesting post
hey teaks! its been a while, hope all is well ... you still holding DRSV??
WHEN WILL TOMZ BRING THE PAIN????
Hey ESS! what you saying??
LBSR dipping slightly for now
you just watching LBSR? what else you holding? anything exciting??
Seems like things are looking awesome here today!!!
thanks for the letter!!
RightSmile, Inc. (PINKSHEETS: RIGH) (www.RightSmile.com), the leader in Cosmetic Laser Teeth Whitening, introduces DentiGel (http://www.dentigel.com ), a line of teeth whitening products designed exclusively for the Dental Professional through its wholly owned subsidiary DentiGel, LLC.
In a move designed to further expand the market reach of RightSmile®, DentiGel is being introduced to the Professional Dental market. As of 2008 The Kaiser Family Foundation reports that there are 230,000 dentists in the US, of which 190,000 are in a general dental practice. It is the first year goal of RightSmile to see that DentiGel makes a modest penetration of 1% of the total available market... this translates into estimated yearly sales revenues in excess of $10 million dollars.
DentiGel is where Chemistry and Engineering meet to enhance the incidence and experience associated with In-Office Dental Cosmetic Laser Teeth Whitening. Dental professionals have often watched their number of in-office teeth whitening procedures decline, as other competing technologies have emerged and eroded their business. DentiGel puts the Dentist back in the driver's seat, the revolutionary combination of a one-size fits all pre-loaded mouth tray and customized Carbomide Peroxide Gels with extended shelf-life and buffers to reduce the temporary issues associated with teeth whitening, tooth sensitivity and gum hyper-oxidation, coupled with a aggressive price point... allow the Dentist to compete against these market usurpers... DentiGel provides a win-win solution for the Dentist and Patient.
RIGH enjoying a decent trading day so far!
Thats good to hear! let me know whats up!! what you holding? whats new???
seems like big big things are expected for long term holders!
production is the name of the game ...
Big things to come, interesting trading going on there
Great alert! good news out this morning!
I'm watching .... I'm watching!
Check out AMNG - Completes Joint Venture With PanPacific Business and Wolfman Jack Entertainment of Hong Kong
http://finance.yahoo.com/news/Amergence-Completes-Joint-iw-950126483.html?x=0&.v=1
well, enjoy your trading day!! I'll bug ya a bit later!
Patience. whats that??
Being talked about alot, big things are brewing!!
Yes yes yes ... I know the thoughts on bouncing from play to play ... its tough though when you are impatient ...
I like the recent news, I'm just holding a very small position
My ears are always open ... keep me posted ...
CPHG needs to get something going!!
you dont change around too much huh?? might not be a bad strategy at all
Brazil Gold Corp. (OTC Bulletin Board:BRZG.ob - News) ("Brazil Gold" or the "Company") is pleased to announce that it has closed on the acquisition of Amazonia Capital e Partipacoes Ltda. ("Amazonia") of Brazil. The transaction gives Brazil Gold ownership rights to 99% of Amazonia, the owner of the exclusive rights to explore an extensive 2.1 million acre land package of mineral rights in the Amazon Basin region of Brazil.
Phillip Jennings, VP and Director of Brazil Gold stated, "The process was lengthy but well worth it. The Company knew it was acquiring an extraordinary asset in one of the hottest mineral plays on the planet. In addition, the acquisition brings into Brazil Gold a world-class, experienced exploration team, with almost a decade of successful exploration operations in the Amazon."
Brazil Gold acquired its ownership in an agreement with Rusheen Handels AG, a Swiss corporation, which owned 99% of all of the issued and outstanding share capital of Amazonia, a Brazilian corporation. Rusheen receives 44 million shares of the Company's common stock. Prior to the closing of this agreement to acquire Amazonia, the Company cancelled 44 million of its restricted shares, which were returned to treasury.
With the transaction, Brazil Gold will be the owner of approximately 2,125,000 acres of mineral claims located in three states in the prolific Tapajos Greenstone Belt in the Amazon Basin. This area encompasses a total of 102 mining claims in the three western states of Amazonas, Mato Grosso, and Rodonia. The primary mineral target is gold, however copper, nickel, iron ore, manganese and cassiterite (tin) are also found in the area. Most of Brazil Gold's properties are near existing roads and rivers which have access to international ports, as well as to small mining and farming communities, thereby giving the Company access to fuel, energy and manpower - conditions which are suitable for low-cost bulk tonnage mining.
Amazonia's prospecting and exploration team selected the tenured areas for exploration because of the numerous producing or previously producing gold mines on the lands which have been operated by local indigenous hand miners, known as garimpeiros.
"The Brazil Gold team is excited to complete this acquisition. After months of due diligence and auditing procedures, we can now concentrate the Company's energy on the exploration initiatives, already underway in some locations, and take advantage of a very propitious time for gold exploration activity," added Mr. Jennings.
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced topline biopsy data from study 28, the ongoing Phase 1b/2 clinical trial of AVI-4658, AVI's lead drug candidate being developed as a systemically administered treatment for a substantial subgroup of patients with Duchenne muscular dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce dystrophin. Topline biopsy data from the study demonstrated the first ever reported generation of new dystrophin-positive muscle fibers of more than 50% of normal in a patient with DMD following systemic administration of a drug. All patients in the two highest dose cohorts of the study demonstrated generation of new dystrophin-positive muscle fibers, although treatment responses varied across and within treatment groups. Generation of functional dystrophin is considered critical for successful treatment of DMD, and AVI intends further clinical evaluation of AVI-4658 to help optimize a dosing regimen to achieve more consistent improvements among patients.
Patients completing 12 weeks of treatment with six different doses of AVI-4658 (0.5, 1.0, 2.0, 4.0, 10 or 20 mg/kg) had their muscles biopsied before and after treatment, and analysis of the post treatment biopsy findings include:
Data reported today for the patients in the 10 and 20 mg/kg drug-treatment cohorts completing the 12 weekly doses (8 of 8 patients) showed consistent skipping of exon 51 in the dystrophin mRNA, providing evidence of systemic biologic activity of AVI-4658.
Three patients, one each in the 2.0, 10 and 20 mg/kg cohorts, demonstrated substantial generation of new dystrophin-positive muscle fibers, including the first ever reported generation of dystrophin-positive muscle fibers of more than 50% of normal in a patient following systemic administration of a drug.
Based on contracts already signed in 2010, NaeroDynamics, Inc. (Pinksheets:NDYN - News) and its wholly owned subsidiary IE Telco Solutions, Ltd. (IETS) are expecting to report significant revenues for the third and fourth quarter of 2010.
In the first and second quarters of 2010, NDYN and IETS made solid progress by winning new Telecom Expense Management (TEM) contracts and performing on their existing contracted customer base. As stated by Co-CEO's Lee Wiskowski and Doug Stukel in March 2010, "These contracts should provide millions of dollars in revenues, expected to be reflected in NDYN's third and fourth quarter revenue reports. Furthermore, NDYN expects to sign major additional contracts this year with well known telecom carriers. The IETS pipeline is robust with a number of major prospective customers."
"The contracts call for IETS to receive a percentage of the savings realized by our customers based upon identifying incorrect billings to our customers from their suppliers. Our preliminary data suggests that substantial savings can be achieved for our major customers, however it should be noted that it in most cases, it is up to the customer to implement the savings after we provide the necessary data and analysis, which is not wholly within IETS' control, and which could impact the timing, magnitude and realization of the fees earned by IETS."